CClinicalTrials.gg
CompletedNCT03453424Updated Mar 23, 2020

Analgesic Efficacy of Dexmedetomidine Added to Fentanyl in PCEA

A Phase 2/3 interventional study of TEA+DEX and TEA in Abdominal Pain and Abdominal Cancer, sponsored by South Egypt Cancer Institute. Completed at 1 site in Egypt. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2020-03-23.

Sponsored by South Egypt Cancer Institute · Phase 2/3, Interventional, and Prevention

Phase
Phase 2/3
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Study summary

Dexmedetomidine if add to patient controlled epidural analgesia for patients undergoing major abdominal cancer surgery may improve its effects.

Read the detailed description

The aim of modern anaesthetic practice is to insure the rapid recovery of patients with fewer complications and earlier hospital discharge.

Thoracic epidural anesthesia (TEA) has been established as a cornerstone in the perioperative care after thoracic and major abdominal surgery providing most effective analgesia. beyond its analgesic properties, TEA's effects on the postoperative neurohumoural stress response, cardiovascular Pathophysiology, and intestinal dysfunction have been in the focus of both clinical and experimental investigations for years.

dexmedetomidine if add to patient controlled epidural analgesia for patients undergoing major abdominal cancer surgery may improve its effects.

02

Conditions studied

  • Abdominal Pain
  • Abdominal Cancer

Browse trials for

03

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • adult patients (21 years old or more),
  • classified as American Society of Anesthesiologists (ASA) grade II and III,
  • scheduled for elective major abdominal cancer surgery.

Exclusion criteria

Exclusion Criteria:

  • patients with coagulopathy,
  • active neurological disease,
  • cutaneous disorders at the epidural insertion site,
  • allergy to the study medication
  • and patients refusal.
04

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
90 participants (actual)

Study arms

  • Active comparator
    TEA+DEX group

    Intra operative thoracic epidural injection of (bupivacaine 0.125% +fentanyl 2 mic/ ml) , initial bolus dose of 8 ml before skin incision followed by fixed rate infusion of 6 ml/h till end of abdominal layer closure. Postoperative, thoracic epidural injection of (bupivacaine 0.0625%+fentanyl 2 mic /ml + dexmedetomidine 0.5 mic/ ml) at infusion rate 6 ml /h and bolus dose of 3 ml with lockout time 10 min

    Procedure: TEA+DEX

  • Active comparator
    TEA group

    Intraoperative,thoracic epidural injection of bupivacaine (0.125%+fentanyl 5 mic/ml ) ,initial bolus dose of 8 ml before skin incision followed by fixed rate infusion of 6 ml/h till start of abdominal layer closure. Postoperative, thoracic epidural injection of (bupivacaine 0.0625%+fentanyl 2 mic /ml) at infusion rate 6 ml /h and bolus dose of 3 ml with lockout time 10 min

    Procedure: TEA

Interventions

  • ProcedureTEA+DEX

    intra and post operative TEA infusion of (bupivacaine +fentanyl 2 mic/ ml+ dexmedetomidine 0.5 mic/ ml) Under strict aseptic precautions thoracic epidural was performed using a 16 gauge,Tuhy epidural needle by a paramedian approach. T8-T9 inter space was chosen for the injection. Skin at insertion site was anesthetized by 3 ml of lidocaine 1%, the epidural space was identified by the loss of resistance technique, the catheter was introduced approximately 2-4 cm into the epidural space, epidural test dose consisted of 3 ml of lidocaine 2 % with 1: 200,000 adrenaline.

  • ProcedureTEA

    Under strict aseptic precautions thoracic epidural was performed using a 16 gauge,Tuhy epidural needle by a paramedian approach. T8-T9 interspace was chosen for the injection. Skin at insertion site was anesthetized by 3 ml of lidocaine 1%, the epidural space was identified by the loss of resistance technique, the catheter was introduced approximately 2-4 cm into the epidural space, epidural test dose consisted of 3 ml of lidocaine 2 % with 1: 200,000 adrenaline. then, intra and post operative TEA infusion of bupivacaine 0.125%+fentanyl 2 mic/ ml.

05

What researchers measure

Primary outcomes

  1. Change in pain scores (dynamic VAS)

    dynamic visual analogue scale (0-10) 0=no pain 10=worst imaginable pain

    Time frame: at 0, 4, 8, 12, 18, 24, 36 and 48 hours post operative.

Secondary outcomes

  1. Change in post operative MAP

    Mean arterial pressure

    Time frame: at 0, 4, 8, 12, 18, 24, 36 and 48 hours post operative.

06

Study locations

1 site
  • South Egypt Cancer Institute, Assiut University, Arab Republic of Egypt
    Assiut, Egypt
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03453424
Lead sponsor
South Egypt Cancer Institute
Responsible party
Alaa Ali M. Elzohry (Principal Investigator, South Egypt Cancer Institute) — Principal investigator
First posted
Mar 5, 2018
Start date
Jun 30, 2017
Primary completion
May 10, 2019
Completion
May 30, 2019
Last update
Mar 23, 2020

Study contacts

Alaa M. Elzohry, MD
principal investigator · Lecturer in Assuit university

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion